RAD51 and cholangiocarcinoma: Increased RAD51 foci have been documented in FGFR2 driven cholangiocarcinoma cells exposed to ionising radiation [53], and similar findings were reported in an imatinib-resistant GIST patient-derived xenograft harbouring FGFR2 TACC2.